Vytorin News and Research

RSS
Vytorin is one tablet that combines two cholesterol-lowering drugs-simvastatin (Zocor), a statin made by Merck & Co., and ezetimibe (Zetia), made by Schering-Plough Pharmaceuticals-to help lower bad cholesterol (low-density lipoprotein, or LDL) further. Simvastatin works in the liver to prevent the formation of cholesterol (as do all statin medications), while ezetimibe works by preventing the absorption of cholesterol from the intestine.
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

Adding ezetimibe to statin therapy reduces cardiovascular events

Adding ezetimibe to statin therapy reduces cardiovascular events

Rare gene mutation linked to lower cholesterol levels, reduced risk of heart attack

Rare gene mutation linked to lower cholesterol levels, reduced risk of heart attack

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

U.S. District Court rules in favor of Merck over ZETIA and VYTORIN patent litigation

U.S. District Court rules in favor of Merck over ZETIA and VYTORIN patent litigation

Merck fails to get FDA nod for new cholesterol lowering combo pill

Merck fails to get FDA nod for new cholesterol lowering combo pill

Merck’s cholesterol lowering drug gets FDA panel’s vote

Merck’s cholesterol lowering drug gets FDA panel’s vote

FDA EMDAC votes to recommend approval of Merck's VYTORIN for pre-dialysis CKD

FDA EMDAC votes to recommend approval of Merck's VYTORIN for pre-dialysis CKD

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck reports GAAP net income of $861 million for 2010

Merck reports GAAP net income of $861 million for 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

VYTORIN reduces major vascular events in patients with chronic kidney disease

Surveyed cardiologists, PCPs perceive Crestor comparable to Lipitor in ability to reduce mortality

Surveyed cardiologists, PCPs perceive Crestor comparable to Lipitor in ability to reduce mortality

Merck reports $342 million net income for 2010 third quarter

Merck reports $342 million net income for 2010 third quarter

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.